Paul R. Lockman
Department of Basic Pharmaceutical Sciences,
School of Pharmacy,
Department of Basic Pharmaceutical Sciences, School of Pharmacy
West Virginia University
Dr. Lockman earned his B.S. in Nursing from West Texas A&M University, after which he practiced in intensive care, clinical toxicology and emergency medicine, then went on to earn his Ph.D. (Pharmaceutical Sciences) at Texas Tech University Health Sciences Center. Dr. Lockman was an Associate Professor and Associate Dean for Outcomes Assessment and Accreditation at Texas Tech University before transitioning to West Virginia University. Currently, Dr. Lockman is the Mylan Endowed Chair of Pharmacology at West Virginia University School of Pharmacy. He also serves as an Assistant Vice of Experimental Director for Translational Research at West Virginia University . Dr. Lockman’s primary research focus is on understanding why chemotherapy has limited distribution, and ultimately fails in brain metastases of breast cancer.
Novel treatment strategies for brain tumors and metastases.
Pharmaceutical patent analyst May, 2014 | Pubmed ID: 24998288
Complex issues affecting student pharmacist debt.
American journal of pharmaceutical education Sep, 2014 | Pubmed ID: 25258436
A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier.
Cancer prevention research (Philadelphia, Pa.) Jan, 2015 | Pubmed ID: 25348853
Report of the 2013-2014 Academic Affairs Committee.
American journal of pharmaceutical education Dec, 2014 | Pubmed ID: 25657388
Molecular determinants of blood-brain barrier permeation.
Therapeutic delivery , 2015 | Pubmed ID: 26305616
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
BMC cancer Oct, 2015 | Pubmed ID: 26463521
Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer.
Clinical & experimental metastasis Apr, 2016 | Pubmed ID: 26944053
Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2016 | Pubmed ID: 27245829
Semi-automated rapid quantification of brain vessel density utilizing fluorescent microscopy.
Journal of neuroscience methods 09, 2016 | Pubmed ID: 27321229
Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
Pharmaceutical research 12, 2016 | Pubmed ID: 27528392
Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors.
Cancer research 01, 2017 | Pubmed ID: 27815391
Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer.
Current cancer drug targets , 2017 | Pubmed ID: 27903215
Permeability across a novel microfluidic blood-tumor barrier model.
Fluids and barriers of the CNS Jan, 2017 | Pubmed ID: 28114946
Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden.
Frontiers in pharmacology , 2017 | Pubmed ID: 28443023
A mouse Model of Focal Vascular Injury Induces Astrocyte Reactivity, Tau Oligomers, and Aberrant Behavior.
Archives of neuroscience Apr, 2017 | Pubmed ID: 28758136
Trastuzumab distribution in an and model of brain metastases of breast cancer.
Oncotarget Oct, 2017 | Pubmed ID: 29137378
Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Pharmaceutical research Jan, 2018 | Pubmed ID: 29368289
Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.
Pharmacological research 06, 2018 | Pubmed ID: 29604436
An Effective Approach to Teaching Pharmacogenomics in the First Year of Pharmacy Curriculum.
American journal of pharmaceutical education 10, 2018 | Pubmed ID: 30425398
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
Oncogene 03, 2019 | Pubmed ID: 30467378
Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer.
BMC cancer Dec, 2018 | Pubmed ID: 30526520
Long non-coding RNA FAM83H-AS1 is regulated by human papillomavirus 16 E6 independently of p53 in cervical cancer cells.
Scientific reports 03, 2019 | Pubmed ID: 30842470
Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment.
Journal of central nervous system disease , 2019 | Pubmed ID: 31007531
Development of a Cx46 Targeting Strategy for Cancer Stem Cells.
Cell reports 04, 2019 | Pubmed ID: 31018124
Improving CNS Delivery to Brain Metastases by Blood-Tumor Barrier Disruption.
Trends in cancer 08, 2019 | Pubmed ID: 31421906
MiR-34a Interacts with Cytochrome c and Shapes Stroke Outcomes.
Scientific reports 02, 2020 | Pubmed ID: 32094435
Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.
BMC cancer Apr, 2020 | Pubmed ID: 32264860
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved